Advertisement

Advertisement

breast cancer
supportive care

Kristin Rojas, MD, FACS, on Improving Sexual Health During Breast Cancer Treatment

Kristin Rojas, MD, FACS, of the University of Miami, shares key points from her discussion on improving sexual health during breast cancer treatment. Dr. Rojas is an Associate Professor of Surgery in the DeWitt Daughtry Family Department of Surgery, Division of Surgery, Miller School of Medicine at University of Miami Health System. She presented her talk at the Annual International Congress on the Future of Breast Cancer East. 

breast cancer

Joseph A. Sparano, MD, FACP, on Premenopausal HR+ Early Breast Cancer: What to Do Outside the OFSET Trial?

Joseph A. Sparano, MD, FACP, of Icahn School of Medicine at Mount Sinai, discusses his presentation on premenopausal patients with hormone receptor–positive early breast cancer. Dr. Sparano is the Ezra M. Greenspan, MD, Professor in Clinical Cancer Therapeutics, Chief of the Division of Hematology Oncology, and Deputy Director of the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai in New York. He presented his talk at the Annual International Congress on the Future of Breast Cancer East. 

breast cancer

Paolo Tarantino, MD, on the Current and Future Landscape of Antibody-Drug Conjugates

Paolo Tarantino, MD, of Dana-Farber Cancer Institute and Harvard Medical School, shares key points from his discussion on the current and future landscape of antibody-drug conjugates. Dr. Tarantino is an Advanced Research Fellow in the Breast Oncology Program at Dana-Farber Cancer Institute and Harvard Medical School. He is also affiliated with the European Institute of Oncology. Dr. Tarantino presented his talk at the Annual International Congress on the Future of Breast Cancer East. 

breast cancer

Aditya Bardia, MD, MPH, FASCO, on Novel Therapies Targeting the Estrogen Receptor

Aditya Bardia, MD, MPH, FASCO, of UCLA Health/Jonsson Comprehensive Cancer Center, shares key points from his discussion on novel therapies targeting the estrogen receptor. Dr. Bardia is Professor, Department of Medicine, Division of Hematology/Oncology, and Director of Translational Research Integration. He presented his talk at the Annual International Congress on the Future of Breast Cancer West. 

Breast Cancer

Tailored Dose-Dense Adjuvant Chemotherapy in High-Risk Early Breast Cancer

As reported in the Journal of Clinical Oncology by Matikas et al, the prespecified end-of-study analysis of the European phase III PANTHER trial showed significant improvements in outcomes with tailored dose-dense vs standard adjuvant chemotherapy in patients with high-risk early breast cancer. As...

Breast Cancer
Genomics/Genetics

Early Breast Cancer: Genetic Testing and Communication of Results With Family After Diagnosis

In a U.S. study reported in the Journal of Clinical Oncology, Steven J. Katz, MD, MPH, and colleagues found that many women with early breast cancer and indications for genetic testing do not undergo said testing. Study Details    The study involved data from 1,412 women aged 20 to 79 years...

Breast Cancer
Survivorship
Genomics/Genetics

Are Eligible Breast Cancer Survivors Receiving Genetic Testing?

Researchers have found that many eligible breast cancer survivors may not be receiving genetic counseling and testing, according to a recent study published by Katz et al in the Journal of Clinical Oncology. Background A growing proportion of cancer treatment and survivorship care relies on...

Genomics/Genetics
Breast Cancer
Gynecologic Cancers
Colorectal Cancer
Solid Tumors

Uncovering the Genetic Risk of Hereditary Breast and Ovarian Cancer Syndrome, Lynch Syndrome

Some patients with a genetic predisposition for cancer may not qualify for genetic screenings under the current guidelines, according to a recent study published by Samadder et al in JCO Precision Oncology. Researchers are investigating how to advance personalized medicine and tailor prevention and ...

breast cancer
immunotherapy

Heather McArthur, MD, MPH, on Immunotherapy for High-Risk, Early-Stage Breast Cancer

Heather McArthur, MD, MPH, talks about immunotherapy for high-risk, early-stage breast cancer. Dr. McArthur is Associate Professor in the Department of Internal Medicine and Clinical Director of the Breast Cancer Program at Simmons Cancer Center at UT Southwestern Medical Center, Houston. She presented her talk at the Annual International Congress on the Future of Breast Cancer West. 

breast cancer

Aditya Bardia, MD, MPH, FASCO, on the Current and Future Landscape of Antibody-Drug Conjugates

Aditya Bardia, MD, MPH, FASCO, of UCLA Health/Jonsson Comprehensive Cancer Center, shares key points from his discussion on the current and future landscape of antibody-drug conjugates. Dr. Bardia is Professor, Department of Medicine, Division of Hematology/Oncology, and Director of Translational Research Integration. He presented his talk at the Annual International Congress on the Future of Breast Cancer West. 

Breast Cancer
Genomics/Genetics

New Genetic Test May Predict Response to Immunotherapy in Triple-Negative Breast Cancer

The search for biomarkers of response to immunotherapy is high on the list of cancer-related research efforts. A new classifier in triple-negative breast cancer is showing promise and is currently being validated in the I-SPY2.2 trial, according to Laura van ’t Veer, PhD, Professor of Laboratory...

Breast Cancer
Issues in Oncology
Supportive Care

Testosterone Therapy May Protect Against Breast Cancer in Transmasculine Patients

Gender-affirming testosterone therapy may have a potential protective benefit in transmasculine patients at risk of breast cancer, according to a recent study published by Heng et al in Breast Cancer Research. Background To treat their gender dysphoria, some transmasculine patients undergo...

Breast Cancer
Geriatric Oncology

Electronic Health Record–Based Prompt May Help Reduce Breast Cancer Overtreatment

Researchers have developed a novel prompt, embedded in electronic health records, to flag older patients with early-stage breast cancer who may be at risk of unnecessary sentinel lymph node biopsy, according to a recent study published by Carleton et al in JAMA Surgery.  Background “In breast...

Breast Cancer

A Role for Avelumab in Triple-Negative Breast Cancer?

In patients with triple-negative early breast cancer deemed to be at high risk for recurrence, 1 year of adjuvant avelumab did not significantly improve disease-free survival but did significantly improve overall survival and risk of distant disease–free survival events. The results from the...

Breast Cancer
Issues in Oncology
Supportive Care

Hormone-Modulating Therapy May Be Linked to Lower Dementia Risk in Patients With Breast Cancer

Hormone-modulating therapy used to treat patients with breast cancer may be associated with a 7% lower risk of developing Alzheimer’s disease and related dementias later in life, according to a recent study published by Cai et al in JAMA Network Open. Background About 67% of patients with breast...

Breast Cancer
Supportive Care

Premenopausal Women With Breast Cancer Receiving Estradiol Suppression Therapy: Effect of Denosumab on Bone Loss

In an Australian single-center trial reported in the Journal of Clinical Oncology, Ramchand et al found that denosumab prevented bone loss vs placebo in premenopausal women with estrogen receptor–positive breast cancer receiving estradiol suppression therapy. Study Details In the double-blind...

Breast Cancer
Genomics/Genetics

Outcomes for BRCA Pathogenic Variant Carriers Undergoing Breast-Conserving Therapy

In a single-center study reported in JAMA Network Open, Kerollos Nashat Wanis, MD, PhD, and colleagues found that women with breast cancer and a pathogenic BRCA1/2 variant who underwent breast-conserving therapy had a 71% rate of 10-year bilateral mastectomy–free survival. Study Details The study...

Breast Cancer

Stage I HER2-Positive Breast Cancer: Long-Term Follow-up of Adjuvant T-DM1

In a 5-year update of the phase II ATEMPT trial reported in the Journal of Clinical Oncology, Tarantino et al found that 1 year of adjuvant ado-trastuzumab emtansine (T-DM1) was associated with “outstanding” long-term outcomes in patients with stage I HER2-positive breast cancer. Study Details In...

Breast Cancer
Issues in Oncology

Predicting Taxane-Induced Peripheral Neuropathy After Breast Cancer Therapy

Researchers have developed a novel tool that may help to predict the risk of experiencing peripheral neuropathy following treatment with taxanes in patients with breast cancer, according to a recent study published by Engvall et al in npj Precision Oncology. The findings may aid physicians in...

Breast Cancer

Predictive Models for Disease Recurrence After Breast-Conserving Surgery for DCIS

In a Canadian study reported in the Journal of Clinical Oncology, Hahn et al evaluated the impact of certain predictive models for local and invasive local recurrence in patients undergoing breast-conserving surgery with or without adjuvant radiotherapy for pure ductal carcinoma in situ (DCIS)....

Breast Cancer

Capivasertib With Fulvestrant for Previously Treated Advanced Hormone Receptor–Positive, HER2-Negative Breast Cancer

On November 16, 2023, capivasertib (Truqap) was approved for use with fulvestrant for patients with hormone receptor–positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations, following disease progression on at least one endocrine-based...

Breast Cancer

Novel Antibody-Drug Conjugate Extends Survival vs Chemotherapy in Triple-Negative Breast Cancer

The antibody-drug conjugate sacituzumab tirumotecan extended overall survival as well as progression-free survival vs chemotherapy in patients with previously treated triple-negative breast cancer, according to the results of OptiTROP-Breast01, a phase III study presented at the 2024 ASCO Annual...

Breast Cancer

Factors Impacting Adherence to Adjuvant Endocrine Therapy in Premenopausal Women With Breast Cancer

In a Danish study reported in the Journal of Clinical Oncology by Schmidt et al, it was found that living alone and being unemployed were associated with reduced adherence to adjuvant endocrine therapy among premenopausal women with breast cancer. Study Details The study involved data from a...

Breast Cancer
Supportive Care
Symptom Management
Genomics/Genetics

Germline Risk of Taxane-Induced Peripheral Neuropathy in Black Women With Early-Stage Breast Cancer

Results from the ECOG-ACRIN EAZ171 trial—reported in the Journal of Clinical Oncology by Schneider et al—showed that germline predictors of taxane-induced peripheral neuropathy were not associated with an increased risk of taxane-induced peripheral neuropathy in Black women with early-stage breast...

Breast Cancer
Issues in Oncology

American Indian and Alaskan Native Women May Be Less Likely to Undergo Breast Reconstruction

Investigators have identified disparities in the rates of breast reconstruction following mastectomy among American Indian and Alaskan Native women compared with non-Hispanic White women, according to a recent study published by White et al in Plastic and Reconstructive Surgery. Background Breast...

Breast Cancer
Supportive Care
Symptom Management
Integrative Oncology

Tai Chi vs Cognitive Behavioral Therapy: Measuring Inflammatory Biomarkers in Breast Cancer Survivors With Insomnia

Both tai chi and cognitive behavioral therapy may reduce insomnia and inflammation and bolster antiviral defenses in breast cancer survivors, according to a recent study published by Irwin et al in Brain, Behavior, and Immunity.   Background Chronic insomnia—one of the most prominent symptoms...

Breast Cancer

Primary Breast Cancer: Pretreatment Exercise Level and Distant Recurrence–Free Interval

In a French study (CANTO) reported in the Journal of Clinical Oncology, Soldato et al found that increasing pretreatment exercise levels was associated with a longer distant recurrence–free interval up to a threshold exercise level in patients with primary breast cancer. The benefit of exercise...

breast cancer

Milana Bergamino Sirvén, MD, PhD, on HER2-Positive Early-Stage Breast Cancer: Molecular Profiling, Prognosis, and Treatment Options

Milana Bergamino Sirvén, MD, PhD, of Spain’s Institute of Cancer Research, discusses her findings on molecular profiling of patients with estrogen receptor–positive, HER2-positive early-stage breast tumors after short-term preoperative endocrine therapy. This study suggests that such profiling may help clinicians identify those patients with a favorable prognosis for adjuvant endocrine therapy and those who may require additional treatment (Abstract 560).

breast cancer

Ciara C. O’Sullivan, MD, MBBCh, on HER2-Positive Breast Cancer: Expert Commentary on Treatments Under Study

Ciara C. O’Sullivan, MD, MBBCh, of Mayo Clinic, discusses three studies of treatment for patients with HER2-positive metastatic breast cancer and their clinical implications: the EMERALD trial of eribulin and taxane; the Patricia Cohort C trial of palbociclib plus trastuzumab and endocrine therapy; and DB07 on trastuzumab deruxtecan with or without palbociclib.

Breast Cancer
Issues in Oncology

Can Chemotherapy Impact the Gut Microbiome in Patients With Breast Cancer?

Researchers have uncovered the impact of chemotherapy on the gut microbiome in patients with breast cancer, according to a recent study published by Otto-Dobos et al in Brain, Behavior, and Immunity. Background Chemotherapy is known to cause behavioral side effects, including cognitive decline....

Breast Cancer

Phase III postMONARCH Trial: Switching to Abemaciclib May Improve Outcomes After Disease Progression

For hormone receptor–positive, HER2-negative advanced breast cancer that has progressed on CDK4/6 inhibition plus endocrine therapy, the CDK4/6 inhibitor abemaciclib plus fulvestrant significantly reduced the risk of further disease progression in the phase III postMONARCH study.1 “The postMONARCH ...

Breast Cancer

ER-Positive Advanced Breast Cancer: Oral SERD Plus Palbociclib in First-Line Setting

As reported in the Journal of Clinical Oncology by Javier Cortés, MD, PhD, and colleagues, the phase III AMEERA-5 trial of first-line treatment with the selective estrogen receptor degrader (SERD) amcenestrant plus palbociclib vs letrozole plus palbociclib in estrogen receptor (ER)-positive,...

Breast Cancer
Supportive Care
Symptom Management

Can Acupuncture Improve Hormonal Side Effects in Women Undergoing Breast Cancer Therapy?

Acupuncture may be effective at reducing the hormonal side effects of endocrine therapy in women with breast cancer, according to a recent study published by Lu et al in Cancer.   Background Although endocrine therapy—which is capable of blocking the hormone signaling that drive some types of...

Breast Cancer
Survivorship

Long-Term Study Finds Most Breast Cancer Survivors Were Able to Preserve Fertility and Achieve Pregnancy After Diagnosis

Research examining fertility and attempts at pregnancy among young women after a breast cancer diagnosis has been hampered by short-term follow-up and a lack of prospective assessment of pregnancy attempts. However, a long-term study investigating fertility outcomes among young women who reported...

Breast Cancer

Addition of Adjuvant Ribociclib to Nonsteroidal Aromatase Inhibitor Therapy Improves Survival in Early Breast Cancer

As reported in The New England Journal of Medicine by Dennis Slamon, MD, PhD, of the David Geffen School of Medicine at the University of California, Los Angeles, and colleagues, interim analysis of the phase III NATALEE trial has shown improved invasive disease–free survival with the addition of...

Breast Cancer

Socioeconomic Disparities in Quality of Life After Early-Stage Breast Cancer Diagnosis

As reported in the Journal of Clinical Oncology by Sandoval et al, after a diagnosis of early-stage breast cancer, the magnitude of preexisting socioeconomic status–related inequalities in quality of life increased over time for patients in the multicentric French CANTO cohort.  “When we talk about ...

Breast Cancer

Oral SERDs Poised to Impact Treatment of Hormone Receptor–Positive Breast Cancer

Suppression of the estrogen receptor has proven to be an effective treatment for hormone receptor–positive breast cancer, but standard endocrine therapies have liabilities that are not limited to their pharmacokinetics or toxicity profiles, which allow for ligand-independent estrogen receptor...

Colorectal Cancer
Breast Cancer
Gynecologic Cancers
Prostate Cancer
Issues in Oncology

Study Evaluates Cancer Screening Behaviors Among a Population of Muslim Individuals

Investigators uncovered crucial insights into the cancer screening behaviors of a population of Muslim individuals residing in the Washington, DC, metropolitan area that could help illuminate the influence of cultural and religious beliefs on health practices, according to a recent study published...

Breast Cancer
Issues in Oncology
Supportive Care

FAPI PET/CT May Improve Staging in Newly Diagnosed Breast Cancer

Researchers have found that fibroblast activation protein inhibitor (FAPI) positron-emission tomography/computed tomography (PET/CT) may offer more accurate staging in patients with newly diagnosed breast cancer than fluorine (F)-18–labeled fluorodeoxyglucose (FDG) PET/CT, according to new findings ...

Breast Cancer

Efficacy of Adjuvant Everolimus Plus Endocrine Therapy in High-Risk, Hormone Receptor–Positive, HER2-Negative Breast Cancer

As reported in the Journal of Clinical Oncology by Mariana Chavez-MacGregor, MD, MSc, FASCO, and colleagues, the phase III SWOG S1207 trial showed no significant benefit in invasive disease–free survival with adjuvant endocrine therapy plus 1 year of everolimus vs 1 year of placebo in patients with ...

Cost of Care
Breast Cancer

Study Documents Decline in Reimbursements for Breast Cancer Surgery From 2003 to 2023

Over the past 20 years, Medicare reimbursements for 10 breast cancer surgical procedures rose by 22%, but inflation rose three times as much—by 69%. Compared with the financial picture had rates kept pace with inflation, the result is an estimated aggregate loss of more than $100 million for breast ...

Breast Cancer

V. Craig Jordan, PhD, ‘the Father of Tamoxifen,’ Dies at Age 76

V. Craig Jordan, CMG, OBE, PhD, DSc, FMedSci, a pioneering scientist whose innovative work in breast cancer research has saved countless lives and will continue to impact the field for generations to come, died on June 9, according to Balkees Abderrahman, MD, PhD, Houston, a friend and colleague of ...

Breast Cancer
Cardio-oncology
Survivorship

Cardiac Dysfunction Among Breast Cancer Survivors

In a study reported in the Journal of Clinical Oncology, Bostany et al found that the cumulative incidence of cardiac dysfunction reached 15.3% at 15 years from the start of cardiotoxic treatments in breast cancer survivors. Study Details The study involved patients at the Next Steps Breast Cancer...

Breast Cancer

Ribociclib Plus Endocrine Therapy vs Combination Chemotherapy in Premenopausal Women With HR-Positive, HER2-Negative Advanced Breast Cancer

As reported by Yen-Shen Lu, MD, PhD, and colleagues in the Journal of Clinical Oncology, final results of the phase II RIGHT Choice study indicate that ribociclib plus endocrine therapy significantly prolonged progression-free survival vs combination chemotherapy in premenopausal women with...

Breast Cancer

Optimizing the Management of DCIS

“Ductal carcinoma in situ (DCIS), once a rare entity, now comprises 20% to 30% of newly diagnosed breast cancers detected on mammography and is appreciated to be a widely heterogeneous disease,” said E. Shelley Hwang, MD, MPH, the Mary and Deryl Hart Distinguished Professor at Duke University, who ...

Breast Cancer
Gynecologic Cancers
Issues in Oncology

Study Finds Early Menopause May Be Linked to Greater Risk of Breast and Ovarian Cancers

The risk of breast cancer and ovarian cancer may be increased in some women who experience early menopause, according to new findings presented by Welt et al at the Endocrine Society’s Annual Meeting & Exposition 2024. Primary ovarian insufficiency is a condition that occurs when a woman’s...

Breast Cancer

Aspirin as Adjuvant Therapy for Breast Cancer

As reported in JAMA by Wendy Y. Chen, MD, MPH, and colleagues, interim analysis of the phase III Alliance A011502 trial has shown no invasive disease–free survival benefit with adjuvant aspirin vs placebo in patients with high-risk nonmetastatic breast cancer. The trial was suspended early due to...

Breast Cancer

Dennis J. Slamon, MD, PhD, Awarded 2024 Szent-Györgyi Prize for Progress in Cancer Research

The National Foundation for Cancer Research (NFCR) announced that the blue-ribbon selection committee, composed of world-renowned research leaders and visionaries, has awarded the 2024 Szent-Györgyi Prize for Progress in Cancer Research to Dennis J. Slamon, MD, PhD, of UCLA Health, for his...

Breast Cancer
Issues in Oncology

Impact of High Blood Insulin Levels on Triple-Negative Breast Cancer Survival in Black Women

High blood insulin levels may contribute to worse outcomes in Black women with triple-negative breast cancer compared with White women with the disease, according to new findings presented by Engel et al at the Endocrine Society’s Annual Meeting & Exposition 2024. Background Triple-negative...

Breast Cancer
Issues in Oncology

Many Breast Cancer Survivors May Experience Excess Weight Gain

Nearly 20% of breast cancer survivors may experience weight gain of more than 10%, according to recent findings presented by Hurtado Andrade et al at the Endocrine Society’s Annual Meeting & Exposition 2024. The research may illuminate a number of factors potentially contributing to excessive...

Advertisement

Advertisement

Advertisement